Illumina, Inc. (NASDAQ:ILMN) Shares Bought by Corient Private Wealth LLC

Corient Private Wealth LLC lifted its holdings in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 302.4% in the fourth quarter, according to its most recent disclosure with the SEC. The institutional investor owned 259,553 shares of the life sciences company's stock after purchasing an additional 195,044 shares during the period. Corient Private Wealth LLC owned approximately 0.16% of Illumina worth $34,684,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of ILMN. Versant Capital Management Inc raised its holdings in Illumina by 153.7% in the fourth quarter. Versant Capital Management Inc now owns 241 shares of the life sciences company's stock valued at $32,000 after acquiring an additional 146 shares in the last quarter. Golden State Wealth Management LLC purchased a new stake in shares of Illumina in the 4th quarter valued at approximately $32,000. Assetmark Inc. raised its holdings in shares of Illumina by 954.8% in the 4th quarter. Assetmark Inc. now owns 327 shares of the life sciences company's stock valued at $44,000 after purchasing an additional 296 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich purchased a new stake in shares of Illumina during the 4th quarter worth $45,000. Finally, TD Private Client Wealth LLC grew its stake in shares of Illumina by 58.5% during the third quarter. TD Private Client Wealth LLC now owns 382 shares of the life sciences company's stock worth $50,000 after purchasing an additional 141 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company's stock.

Illumina Trading Up 3.4 %

Shares of NASDAQ ILMN traded up $2.87 during midday trading on Friday, reaching $87.66. 3,822,331 shares of the stock were exchanged, compared to its average volume of 2,094,739. The stock has a 50 day moving average price of $109.19 and a 200-day moving average price of $128.58. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The company has a market capitalization of $13.89 billion, a P/E ratio of -11.41, a P/E/G ratio of 1.60 and a beta of 1.17. Illumina, Inc. has a 52-week low of $80.18 and a 52-week high of $156.66.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. Equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analyst Ratings Changes

ILMN has been the topic of several research analyst reports. Piper Sandler lifted their price target on shares of Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a research note on Monday, February 10th. HSBC lowered Illumina from a "buy" rating to a "hold" rating and set a $100.00 price objective on the stock. in a report on Friday, February 28th. Canaccord Genuity Group cut their target price on Illumina from $135.00 to $115.00 and set a "hold" rating for the company in a research note on Tuesday, March 11th. Royal Bank of Canada reduced their price target on Illumina from $247.00 to $128.00 and set an "outperform" rating for the company in a report on Wednesday, March 12th. Finally, Robert W. Baird dropped their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating on the stock in a report on Wednesday, March 5th. One analyst has rated the stock with a sell rating, ten have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Illumina has an average rating of "Moderate Buy" and an average target price of $140.90.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.